September 2016September 2016
New Product - Descovy
Descovy (emtricitabine (FTC) and tenofovir alafenamide (TAF) fumarate) contains emtricitabine (FTC) a nucleoside analogue that inhibits HIV replication through incorporation into viral DNA by the HIV reverse transcriptase, which results in DNA chain‑termination. FTC has activity that is specific to human immunodeficiency virus (HIV‑1 and HIV‑2) and hepatitis B virus. Descovy also contains tenofovir alafenamide (TAF) fumarate, a phosphonamidate prodrug of tenofovir, it is permeable into cells and due to increased plasma stability and intracellular activation through hydrolysis by cathepsin A, TAF is more efficient than tenofovir disoproxil fumarate (TDF) in loading tenofovir into peripheral blood mononuclear cells (PBMCs), including lymphocytes and macrophages. Intracellular tenofovir is subsequently phosphorylated to the pharmacologically active metabolite tenofovir diphosphate. Tenofovir diphosphate inhibits HIV replication through incorporation into viral DNA by the HIV reverse transcriptase, which results in DNA chain‑termination. Descovy is indicated in combination with other antiretroviral agents for the treatment of HIV‑1 infection in adults and adolescents aged 12 years and older with a body weight of at least 35 kg. The patients must not have a history of treatment failure or known mutations associated with resistance to the individual components of Descovy. Descovy is not for use in pre‑exposure prophylaxis (PrEP). Descovy is available as Descovy 200/10 mg tablets contianing 200 mg of FTC and 10 mg of TAF respectively and Descovy 200/25 mg tablets containing 200 mg of FTC and 25 mg of TAF respectively in bottles of 30’s.
Copyright © MIMS Australia Pty Ltd. All rights reserved.
MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629
info@mims.com.au
www.mims.com.au